Sant Joan D'alacant

• Randomized clinical trial to assess the efficacy and safety of a strategy for primary prevention of cardiovascular disease in patients with … Pending
  2025-521086-28-00 6 CHRONIC INFLAMMATORY RHEUMATIC DISEASE: rheumatoid arthritis or psoria
• Grass Immunotherapy for Rhinitis and Asthma (GIRA) Pending
  2025-521736-10-00 5 Allergic rhinoconjunctivitis with or without controlled asthma
• Clinical trial to assess the efficacy and safety of a vaccine for dust mite and Lepidoglyphus destructor allergy. Pending
  2025-522771-28-00 5 Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoco
• Phase III clinical trial to evaluate the efficacy and safety of specific immunotherapy with mannanconjugated allergoids for the treatment of … Recruiting
  2023-508547-51-00 5 2025-11-18 Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoco
• Study to evaluate efficacy and safety of inclisiran in children aged 2 to under 12 years of age with homozygous familial hypercholesterolemi … Recruiting
  2024-514595-41-00 5 2025-08-05 homozygous familial hypercholesterolemia
• A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE … Recruiting
  2024-512360-55-00 4 2025-06-30 Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
• A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec … Recruiting
  2024-512926-27-00 5 2024-12-12 patients with estrogen receptor-positive/human epidermal growth factor
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) … Recruiting
  2023-504323-25-01 5 2024-03-19 breast cancer
• An international investigator initiated trial to capture different approaches in the treatment of Haemophilia A Patients With FVIII Inhibito … Recruiting
  2024-516741-39-00 6 2020-01-14 Haemophilia A
• Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low Breast Cancer Patients Presenting with Newly Diagnosed or Progressing … Ended recruitment
  2023-506702-39-00 4 2024-06-05 HER2-low breast cancer presenting with newly diagnosed or progressing
• Randomized clinical trial assessing the value of Beta-Blockers and Antiplatelet Agents in patients with Spontaneous Coronary Artery Dissecti … Ended recruitment
  2024-516039-28-00 6 2021-09-28 Spontaneous Coronary Artery Dissection.
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer
• A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi … Ended recruitment
  2023-509242-35-00 5 2020-07-23 HR+/HER2- early breast cancer
• Phase II trial of trastuzumab deruxtecan in first-line treatment HER2-positive locally advanced or metastatic breast cancer (MBC) patients c … Ended
  2023-503627-26-00 4 2023-09-28 Metastatic breast cancer
• Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2 … Ended
  2024-512590-27-00 9 2023-03-08 Non-resectable locally advanced or metastatic HER2-positive breast can
• Study to evaluate the efficacy and safety of switching to insulin glargine 300 U/ml from insulin glargine 100 U/ml in patients with type 2 d … Ended
  2024-518403-22-00 6 2022-06-20 Diabetes mellitus II
• Clinical trial developed at various hospitals where each patient randomly receive in parallel groups either placebo or treatment. Nor patien … Ended
  2024-519527-14-00 5 2022-06-09 Allergic rhinoconjunctivitis
• Hemodynamic Phenotype-Based,Capillary Refill Time-Targeted Resuscitation In Early Septic Shock:ANDROMEDA-SHOCK-2 Ended
  2024-519691-10-00 6 2022-05-27 Septic Shock
• A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended
  2024-514372-40-00 5 2022-04-12 Anterior ST-Elevation Myocardial Infarction
• A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. … Ended
  2024-512052-38-00 9 2021-12-02 Advanced triple negative breast cancer
• A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati … Ended
  2023-508472-11-00 5 2018-06-13 Patients with early breast cancer

Showing 1–21 of 21 trials